3
Announcements
Trials
Browse
Landscape
Phase
Phase NA
1
Status
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Vascular Diseases
1
Respiratory Tract Diseases
1
Pulmonary Embolism
1
Neoplasms
1
Lung Diseases
1
Embolism and Thrombosis
1
Embolism
1
Disease
1
Cardiovascular Diseases
1
Interventions
Cyclophosphamide
956
Radiotherapy
847
Cisplatin
757
Gemcitabine
657
Carboplatin
603
Docetaxel
598
Paclitaxel
585
Bevacizumab
580
Fluorouracil
504
Oxaliplatin
458
Rituximab
453
Surveys and Questionnaires
449
Capecitabine
440
Dexamethasone
428
Doxorubicin
424
Etoposide
411
Irinotecan
389
Cytarabine
376
Filgrastim
369
pembrolizumab
328
Leucovorin
305
Nivolumab
296
fludarabine phosphate
294
Melphalan
288
Magnetic Resonance Spectroscopy
280
Peripheral Blood Stem Cell Transplantation
279
Blood Specimen Collection
279
Methotrexate
276
Lenalidomide
276
Cetuximab
270
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Completed
×
OTHER
×
4-((1,4,8,11-tetraazacyclotetradec-1-yl)methyl)benzoic acid
×
Clear all
NCT04657120
2025-12-23
HYDRA
Leiden University Medical Center
Phase NA
Completed
698 enrolled